Criminal Behavior in Early Onset Neurodegenerative Diseases
Funding: This work was supported by The State Research Funding and the Strategic Neuroscience Funding of the University of Eastern Finland, Suomen Aivosäätiö, Roche, Sigrid Juséliuksen Säätiö, Suomen Lääketieteen Säätiö, Wihuri Research Institute, and Suomen Kulttuurirahasto.
ABSTRACT
Introduction
Literature on criminal behavior preceding a neurodegenerative disease diagnosis is insufficient. Some studies suggest increased crime rates among patients with frontotemporal dementia (FTD).
Methods
Patients with neurodegenerative diseases were gathered from Kuopio and Oulu University Hospitals and compared with nonselective general population data from Statistics Finland (N = 24,144). Clinical data were linked to the Finnish national register of police-reported crimes.
Results
In total, 2424 participants with neurodegenerative diseases were included. Overall crime rates were notably higher among patients with FTD during the year before the diagnosis (9.4% for FTD, 6.3% for controls, p = 0.019). There was a significant drop in the criminal rates of FTD patients 3 years after the diagnosis (4.7% in the FTD, 12.3% in controls, p < 0.001).
Discussion
Criminal behavior is overrepresented in patients with FTD before the diagnosis. Criminal behavior manifesting in previously law-abiding individuals in late adulthood should be considered a potential early symptom of a neurodegenerative disease.
1 Background
Neurodegenerative diseases can manifest with neuropsychiatric symptoms, which include, for example, loss of impulse control and foresight, disinterest, and aggressive behavior [1-4]. Changes in behavior may be among the first manifestations of a neurodegenerative disease and pose a great burden not only to the patients themselves but also to society and the legal system [5, 6].
Especially in behavioral variant frontotemporal dementia (bvFTD), neuropsychiatric and behavioral symptoms are common [7, 8]. It has been proposed that these symptoms can predispose an individual to criminal behavior [9]. Previous studies [10-17] and case reports [18] have described increased rates of antisocial and criminal behavior in patients with FTD. However, in these studies, the evaluation has mostly been based on caregivers' interviews or examination of the participants' patient records, and only one of them has included a control group of participants without a neurodegenerative disease [16]. Furthermore, previous knowledge on the crime rates in various other neurodegenerative diseases is limited.
The aim of this case–control study was to examine the frequency and the types of criminal acts in a large cohort of patients consisting of all common neurodegenerative diseases and compare these to matched controls without a neurodegenerative disease. We consider the study ethically justifiable as so far, criminal behavior in these patient groups has not been thoroughly studied and the lack of knowledge can weaken the legal protection of these patients.
2 Methods
2.1 Standard Protocol Approvals, Registrations, and Patient Consents
The study was performed according to the principles of the Declaration of Helsinki. Participants were not identifiable from the data and were not contacted directly. As stated in the Finnish Legislation (552/2019), no consents from the study participants were needed, and thus an independent Ethical Committee evaluation was not required. The study protocol was approved by the Finnish Social and Health Data Permit Authority Findata (THL/2841/14.02.00/2022). This study is part of the DEGE-RWD research project (NCT06209515), coordinated by Neurocenter Finland.
2.2 Study Participants
The study population consisted of patients with a neurodegenerative disease diagnosed at the Kuopio University Hospital (KUH) and Oulu University Hospital (OUH) between the years 2010 and 2021. These hospitals represent tertiary-level neurological clinics and are also the primary regional referral centers for all citizens ≤ 65 years old with neurodegenerative diseases. Thus, in these regions, the diagnostics of early onset neurodegenerative diseases, all amyotrophic lateral sclerosis (ALS), most PD cases, and rare neurodegenerative diseases are performed exclusively within these centers. All patients who visited the neurodegenerative disease outpatient clinics during 2010–2021 (N = 12,490) were identified from the patient registries, and their patient records were retrospectively reviewed one at a time to confirm and validate the diagnoses. The final cohort included all the patients diagnosed with a neurodegenerative disease between 2010 and 2021 (N = 2424). The diagnoses included were all FTD subtypes (bvFTD, nonfluent variant of primary progressive aphasia (nfvPPA), semantic variant of primary progressive aphasia (svPPA), progressive supranuclear paresis (PSP), corticobasal syndrome (CBS), frontotemporal dementia with motor neuron disease (FTD-ALS)), Alzheimer's disease (AD), Parkinson's disease (PD) and Parkinson's disease dementia (PDD), ALS, vascular dementia (VaD) and vascular cognitive impairment (VCI), and dementia with Lewy bodies (DLB). Cases with mild cognitive impairment (MCI) were also included. Patients who did not fulfill the criteria for any of these neurodegenerative diseases were excluded. All patients had undergone thorough diagnostic procedures and had been examined by experienced neurologists specialized in neurodegenerative diseases. The diagnoses were based on the previously published criteria [19-25]. As a control group, nonselected basic population data from Statistics Finland was used. Participants in this group were matched with age, sex, and region, and the participant-toto-control ratio was 1:10 in each group. A diagnosis of neurodegenerative disease was an exclusion criterion when the controls were randomly selected from the corresponding geographical areas. Data gathered from Statistics Finland, including data on police-recorded crimes, were connected to the clinical data by the unique and nationally universal social security number of each patient.
2.3 Criminal Records
Evaluation of the criminal records was done by gathering data from the Statistics Finland register of all police-recorded crimes. Crime was defined as any type of offense against Finnish legislation. The data are complete since a crime cannot be recorded without ending up in the register. Classification of criminal offenses was based on the Statistics Finland system, which enables the evaluation of different types of crimes (violence, crimes against property, drunk driving, traffic violations). By definition, violent crimes include homicide, assault, manslaughter, and robbery. Property crimes include all types of property crimes (theft, shoplifting) except robbery involving violence or a threat of violence. Drunk driving includes all cases of driving under the influence of alcohol with the blood ethanol concentration exceeding 0.05%. All other types of traffic offenses fall into the last category, traffic violations. These data were collected from 1996 to 2020. Data on offenses were gathered from 10 calendar years preceding the year of diagnosis until 3 years after the year of diagnosis.
2.4 Statistical Analyses
Statistical analyses were performed with Stata v.17. Differences in crime prevalence between cases and controls at different follow-up periods were examined using crosstabulations, and the statistical significance of these differences was tested using chi-square tests. While we sought to find 10 matched controls for each individual, for some older individuals a smaller control group was used, which resulted in a variable matching ratio and generally a slightly younger control population. The robustness of the results was tested using conditional logistic regression that accounts for the variable matching ratio.
2.5 Data Availability
Individual-level data cannot be shared outside the research group due to data privacy regulation. Group-level data can be shared upon a reasonable request to the corresponding author.
3 Results
3.1 Participants
After going through the 12,490 patient records and excluding participants not fitting the criteria for any of the included neurodegenerative diseases, the total number of patients included was 2424. See Table 1 for the distribution of the participants among different diagnostic groups.
Diagnosis | N (control n) | Sex, m/f % (control sex, m/f %) | Age at diagnosis, years, mean; SD (control age at diagnosis, years, mean; SD) |
---|---|---|---|
|
563 (n = 5621) | 42.3/57.7 (42.3/57.7) | 62.0; 5.1 (62.0; 5.0) |
FTD
|
297 (n = 2964)
|
55.2/44.8 (55.3/44.7) | 61.3; 6.1 (61.3; 6.1) |
DLB | 60 (n = 600) | 76.7/23.3 (76.7/23.3) | 64.0; 4.1 (64.0; 4.1) |
PD + PDD | 1097 (n = 10,910) | 62.7/37.3 (62.8/37.2) | 59.3; 8.0 (59.3; 8.0) |
ALS | 208 (n = 2080) | 55.3/44.7 (55.3/44.7) | 59.1; 7.8 (59.1; 7.8) |
VaD + VCI | 145 (n = 1437) | 60.7/39.3 (66.3/33.7) | 61.6; 6.0 (61.5; 6.0) |
MCI | 54 (n = 532) | 53.7/46.3 (53.4/46.6) | 62.4; 4.4 (62.3; 4.3) |
- Note: Separate control groups for each diagnostic group were matched with similar age, region, and sex distributions with participant to control with target matching ratio of 1:10.
- Abbreviations: AD, Alzheimer's disease; ALS, Amyotrophic lateral sclerosis; bvFTD, behavioral variant frontotemporal dementia; CBS, corticobasal syndrome; DLB, Dementia with Lewy Bodies; f, female; FTD, frontotemporal dementia; FTD-ALS, frontotemporal dementia with motor neuron disease; lvPPA, logopenic variant of primary progressive aphasia; m, male; MCI, Mild cognitive impairment; N, number of cases; nfvPPA, nonfluent variant of primary progressive aphasia; PD, Parkinson's disease; PDD, Parkinson's disease dementia; PSP, progressive supranuclear palsy; SD, standard deviation; svPPA, semantic variant of primary progressive aphasia; VaD, Vascular dementia; VCI, Vascular cognitive impairment.
Of the whole study population, 1056 (43.6%) were women, and 1368 (56.4%) were men, and 1525 (62.9%) were from OUH, and 899 (37.1%) were from KUH. For each participant with a neurodegenerative disease, 10 control participants without a neurodegenerative disease were included. The numbers of control participants for specific disease groups were 5621 for AD + frontal AD, 2964 for FTD, 600 for DLB, 10910 for PD + PDD, 2080 for ALS, 1437 for VaD + VCI, and 532 for MCI, altogether 24,144 control participants.
3.2 Criminal Behavior Among Different Neurodegenerative Diseases
First, we compared crimes (all crimes combined) in each diagnostic group of neurodegenerative diseases, during 10 and five consecutive calendar years preceding the year before the diagnosis and during the year preceding the diagnosis. The groups were divided into (1) AD (including frontal AD and lvPPA), (2) FTD (all subtypes), (3) DLB, (4) PD + PDD, (5) ALS, (6) VaD + VCI, and (7) MCI. In the period of 10 years preceding the year before the diagnosis, none of the study groups had significantly higher or lower crime rates (all crime types combined) compared to their matched control groups.
We also compared AD (excluding frontal AD) and bvFTD to their control groups separately, resulting in similar overall rates. During the period of five calendar years preceding the year before the diagnosis, more FTD patients committed crimes than the controls, but the difference was not statistically significant (30.6% vs. 26.6%, p = 0.137). However, during the 5-year period, the criminal rates of participants with bvFTD were higher (32.2%, n = 55) than the control group (24.8%, n = 423), p = 0.034. During the calendar year before the diagnosis, the crime rates of patients with FTD significantly exceeded the rates of the control group (9.4% vs. 6.0%, p = 0.019). Patients in the PD + PDD group had a significantly lower crime rate during five calendar years (22.2% vs. 25.3%, p = 0.021) before the year before the diagnosis as well as during the calendar year (4.6% vs. 6.7%, p = 0.006) before the diagnosis compared to controls. All main results are shown in Table 2.
Diagnosis | 10 years, %, n vs. (controls %, n) | 5 years, %, n vs. (controls %, n) | 1 year, %, n vs. (controls %, n) | |
---|---|---|---|---|
FTD, n = 297 (controls, n = 2964) |
42.8%, n = 127 (40.7%, n = 1205) a |
30.6%, n = 91 (26.6%, n = 789) b |
9.4%, n = 28 (6.3%, n = 177) c |
(a) p = 0.481 (b) p = 0.137 (c) p = 0.019 |
bvFTD, n = 171 (controls, n = 1708) |
41.5%, n = 71 (37.7%, n = 643) a |
32.2%, n = 55 (24.8%, n = 423) b |
8.8%, n = 15 (5.7%, n = 98) c |
(a) p = 0.320 (b) p = 0.034 (c) p = 0.112 |
AD + fAD + lvPPA, n = 563 (controls, n = 5621) |
31.8%, n = 179 (35.0%, n = 1969) a |
20.8%, n = 117 (23.1%, n = 1297) b |
5.3%, n = 30 (6.2%, n = 347) c |
(a) p = 0.124 (b) p = 0.217 (c) p = 0.425 |
AD (excluding fAD), n = 551 (controls, n = 5501) |
31.9%, n = 176 (35.2%, n = 1935) a |
21.1%, n = 116 (23.2%, n = 1277) b |
5.4%, n = 30 (6.2%, n = 343) c |
(a) p = 0.129 (b) p = 0.251 (c) p = 0.462 |
DLB, n = 60 (controls, n = 600) |
43.3% n = 26 (45.8%, n = 275) a |
35.0%, n = 21 (30.0%, n = 180) b |
8.3%, n = 5 (6.8%, n = 41) c |
(a) p = 0.711 (b) p = 0.422 (c) p = 0.664 |
PD + PDD, n = 1097 (controls, n = 10,910) |
34.5%, n = 378 (36.9%, n = 4028) a |
22.2%, n = 244 (25.3%, n = 2763) b |
4.6%, n = 50 (6.7%, n = 729) c |
(a) p = 0.107 (b) p = 0.021 (c) p = 0.006 |
VaD + VCI, n = 145 (controls, n = 1437) |
40.7% n = 59 (39.7%, n = 570) a |
22.1%, n = 32 (25.7%, n = 369) b |
4.8%, n = 7 (6.5%, n = 94) c |
(a) p = 0.810 (b) p = 0.341 (c) p = 0.421 |
ALS, n = 208, (controls, n = 2080) |
36.1%, n = 75 (39.3%, n = 817) a |
23.1%, n = 48 (26.1%, n = 543) b |
4.3%, n = 9 (6.5%, n = 135) c |
(a) p = 0.364 (b) p = 0.341 (c) p = 0.221 |
MCI, n = 54 (controls, n = 532) |
33.3%, n = 18 (39.3%, n = 209) a |
16.7%, n = 9 (25.6%, n = 136) b |
7.4%, n = 4 (7.1%, n = 38) c |
(a) p = 0.392 (b) p = 0.149 (c) p = 0.943 |
The crime rates of all disease groups were also compared to the respective group-specific control groups during the three consecutive calendar years after the diagnosis. The total number of cases in these comparisons was different due to mortality. In the AD group, the overall criminality rate was 4.3%, compared to 9.9% in controls (total AD n = 531, p < 0.001). In the FTD group, the criminality rate was 4.7% compared to 12.4% in controls (total FTD n = 235, p < 0.001). In the PD + PDD group, 9.6% of cases and 13.9% of controls had committed crimes (total PD + PDD n = 1063, p < 0.001). The criminal rates were 8.0% in ALS patients and 13.9% in controls (total ALS n = 88, p = 0.113). In the VCI + VaD group, 10.1% of patients and 12.5% of control participants had committed crimes (total VCI + VaD n = 129, p = 0.421). Comparisons in the MCI and DLB groups were not applicable due to the low number of cases.
3.3 Criminal Behavior in FTD
Due to the observed differences in the crime rates, especially in the FTD group (N = 297), subanalyses were conducted. In the FTD group, 133 patients (44.8%) were women and 164 (55.2%) were men. The mean age at diagnosis was 61.3 years. The yearly differences in criminal rates between FTD patients and controls are demonstrated in Figure 1.

Next, we compared the types of crimes in the FTD group, divided as follows: (1) violence, (2) crimes against property, (3) drunk driving, and (4) traffic offenses. We calculated the frequency of all types of crimes during 10 and five calendar years preceding the year of diagnosis and during the year of diagnosis, separately in patients aged 69 years and younger and under 60 years (at diagnosis).
Overall, rates of violent crimes were low among FTD patients during the whole study period, with no statistically significant differences compared to control participants.
Crimes against property were over twice as frequent in the FTD group compared to the control group during the 10-year period preceding the year before the diagnosis (5.4% in FTD patients aged 69 years and younger vs. 2.4% in the control group (p = 0.003)). In the group of participants under 60 years, the numbers were 8.4% for FTD and 3.0% for controls (p = 0.004). During the 5 years preceding the year before the diagnosis, property crimes appeared more common in the FTD group (2.7%) compared to the control group (1.4%); however, this was not statistically significant (p = 0.077). In individuals < 60 years of age, the numbers were 5.6% for FTD and 1.8% for controls, and the difference between these groups was statistically significant (p = 0.009). During the year before the diagnosis, property crimes were more common in the FTD group (1.3%) than in the control group (0.2%) (p = 0.002). Comparing participants under 60 years, the numbers were 2.8% in the FTD group and 0.4% in the control group (p = 0.002).
During the 10-year period preceding the year before the diagnosis, drunk driving was more common in the FTD group (4.7% of the FTD patients compared to 2.7% in the control group, p = 0.048). The difference was even more significant when comparing participants under 60 years, with percentages of 7.5% for FTD and 2.9% for controls (p = 0.012).
Traffic violations were almost equally common between FTD patients and controls during the 10 and five calendar years preceding the year before the diagnosis, although during the calendar year before the diagnosis, FTD patients showed higher rates of traffic offenses, indicated by 7.7% in the FTD group and 5.0% in the control group (p = 0.049). Among individuals aged < 60 years, 11.2% of FTD patients and 6.2% of controls had committed traffic offenses (p = 0.046) during the year before the diagnosis.
Results for the prevalence of different crime subtypes in FTD patients and control participants are listed in Table 3.
10 years FTD %, n (control %, n) p | 5 years FTD %, n (control %, n) p | 1 year FTD %, n (control %, n) p | |
---|---|---|---|
Violence | |||
2.7% n = 8 (2.2%, n = 64) p = 0.550, NS |
1.0%, n = 3 (0.9%, n = 27) p = 0.864, NS |
N/A | |
Property | |||
5.4%, n = 16 (2.4%, n = 72) p = 0.003 |
2.7%, n = 8 (1.4%, n = 41) p = 0.077, NS |
1.3%, n = 4 (0.2%, n = 7) p = 0.002 |
|
Drunk driving | |||
4.7%, n = 14 (2.7%, n = 80) p = 0.048 |
2.4%, n = 7 (1.7%, n = 51) p = 0.429, NS |
N/A | |
Traffic violations | |||
37.4%, n = 111 (37.0%, n = 1096) p = 0.893, NS |
26.6%, n = 79 (24.0%, n = 715) p = 0.317, NS |
7.7%, n = 23 (5.0%, n = 150) p = 0.049 |
- Note: It was not possible to calculate the rates of violent crimes and drunk driving during the 1 year before diagnosis due to low n. Statistically significant differences are bolded.
- Abbreviations: FTD , frontotemporal dementia; n, number of cases; N/A, not applicable; NS, not significant.
4 Discussion
Here, we have evaluated the prevalence of criminal behavior among a substantially large group of patients with neurodegenerative diseases. Crime rates were found to be higher, especially in FTD patients than in controls several years before the diagnosis. Interestingly, crime rates appear to substantially decrease shortly after the diagnosis, also in the FTD group. To our knowledge, this is one of the most comprehensive studies to examine criminal behavior in these disease groups, including data spanning over a decade before and 3 years after the diagnosis, complete criminal record data as well as a remarkable number of adjusted controls. We used objective data from Statistics Finland and utilized nonselective population data as a control group.
Our results considering FTD patients are in line with previous reports [12, 15, 26, 27]. We separately analyzed the 10 and five calendar years preceding the year before the diagnosis as well as the year before the diagnosis. Patients with FTD committed significantly more criminal offenses, especially during the year before the diagnosis. Some criminal acts were more common even during the period of 10 years prior to the diagnosis year.
The reasons underpinning increased rates of criminal behavior among FTD patients are most likely multifactorial. Diehl-Schmid and colleagues interviewed some of the patients with a history of criminal behavior. Most of them did not feel the need to explain the reasons behind their criminal acts, and none of the patients showed guilt, shame, or remorse [11]. Similarly, Mendez and colleagues described cases of four patients with FTD who had committed criminal acts [18]. All of them understood the wrongfulness and consequences of their actions, yet were not able to refrain themselves from committing criminal acts. Particularly, the frontal lobes are anatomical structures involved in controlling behavior, and as FTD causes progressive damage to these brain areas, it is not surprising that these patients often show inappropriate or even criminal behavior. Disturbances, especially in the prefrontal cortex, have been suggested to underlie these behaviors [18]. Also, other studies support this notion, as emotional dysfunction, deficits in decision-making, and morally improper behavior have been observed in patients with lesions in this area [28-32]. Interestingly, crime rates were lower specifically in patients with PD already several years before diagnosis. This finding seems plausible from a neurobiological perspective, considering the reduced dopaminergic activity in PD, as conversely, increased dopaminergic transmission, induced by, for example, alcohol or cocaine use, is known to increase impulsivity [33].
To our knowledge, there are only two other studies that have previously used nationwide data on police-recorded crimes as a source to assess criminal acts in FTD patients. Talaslahti and colleagues investigated the time period of 4 years before the diagnosis and reported that criminal behavior was more frequent among the group of FTD patients, with 94% of the crimes being traffic offenses or crimes against property [26], but the clinical diagnoses were purely register-based and not re-assessed and validated. Another study in a small cohort from Germany reported a history of criminal behavior in over half (54%) of bvFTD patients and in 56% of svPPA patients, but only in 12% of patients with AD [11]. Although the evaluation of criminal behavior was based on caregiver interviews, the findings are similar to ours as mainly minor (property) crimes and drunk driving were more common in patients with FTD, whereas violent crimes were not associated with FTD or other neurodegenerative diseases.
A previous study also examined crime rates after the diagnosis of a neurodegenerative disease, showing that the number of criminal offenses may be diminished even up to 50% compared to the general population [34]. The results in our present study were parallel, indicating substantially decreased crime rates after diagnosis. This might be explained by the medical surveillance with regular follow-up visits, by the use of symptomatic medication, or closer surveillance by a caregiver [27]. This underlines the importance of early and accurate neurodegenerative disease diagnosis and care. Another possible explanation could be that the patient's condition worsens to the state in which committing crimes may not be physically and/or cognitively possible. Interestingly, one study showed that FTD patients with a reported history of criminality had higher MMSE scores than the ones without, and the disease severity was classified as mild in nearly all patients with criminal acts [15]. This suggests that increased criminality in FTD is emphasized rather as an early symptom of the disease than that of the later dementia phase. Moreover, it has been debated whether there should be a system that would enable examining the possibility of a somatic reason behind the sudden criminal behavior for first-time offenders older than 55–60 years and excluding diseases damaging especially the frontal lobes [11]. Currently, there are no common medical criteria to assess criminal responsibility for people with FTD or other dementias, and the classification of “criminal responsibility” varies between countries. This study raises the question of whether specific criteria should be developed since the phenomenon of criminal behavior in prodromal neurodegenerative disease exists.
The strengths of this study include the comprehensive, well-characterized study groups, including all major neurodegenerative diseases, and the inclusion of a powerful 1:10 case-to-control ratio of nonselected control participants without a diagnosis of a neurodegenerative disease representing the general population. Furthermore, we utilized objective and complete data from Statistics Finland, which leaves only a small chance for reporting bias. All the diagnoses were made in expert-level memory outpatient clinics by experienced neurologists specialized in neurodegenerative diseases, according to the latest diagnostic criteria. All patients were validated by thorough retrospective re-evaluation, substantially increasing the specificity of the diagnoses compared to conventional register-based approaches. The time period reaching 10 years prior to the diagnosis offers insights into the very early (prodromal) phase of the disease. A limitation of this study is the small size of some of the subcohorts, which reduces the statistical power of part of the analyses. Furthermore, although the diagnoses were made in special-level clinics and ascertained with retrospective evaluation of patient records, there is a minor but possible chance for individual misdiagnoses.
In conclusion, this study suggests increased overall criminal rates, especially in patients with FTD during the last year before the diagnosis. Significant differences in drunk driving and property crimes were detectable already 10 years before the diagnosis, proposing that criminal behavior is an early symptom of FTD. Sudden criminal behavior in previously law-abiding individuals during the middle or elderly years of life can be a symptom of a neurodegenerative disease. Therefore, possible organic causes, especially brain disorders damaging the frontal areas of the brain, should be considered as potential underlying reasons. Early and accurate diagnosis may result in decreased criminal behavior, reducing both individual and societal burdens.
Author Contributions
Helmi Soppela: conceptualization, investigation, writing – original draft, validation, writing – review and editing. Mikko Aaltonen: conceptualization, investigation, methodology, formal analysis, writing – review and editing. Kalle Aho: data curation, writing – review and editing, resources. Sami Heikkinen: writing – review and editing, investigation. Ave Kivisild: data curation, resources, writing – review and editing. Adolfina Lehtonen: writing – review and editing, data curation, resources. Laura Leppänen: writing – review and editing, data curation, resources. Anna Mäki-Petäjä-Leinonen: validation, writing – review and editing. Iina Rinnankoski: data curation, resources, writing – review and editing. Laura Tervonen: writing – review and editing, data curation, resources. Jari Tiihonen: validation, writing – review and editing. Markku Lähteenvuo: validation, writing – review and editing. Annakaisa Haapasalo: validation, writing – review and editing, investigation. Anne M. Portaankorva: validation, writing – review and editing, supervision. Päivi Hartikainen: validation, writing – review and editing. Kasper Katisko: validation, writing – review and editing, methodology, conceptualization, funding acquisition, investigation, writing – original draft, supervision. Johanna Krüger: conceptualization, investigation, funding acquisition, methodology, validation, writing – review and editing, supervision. Eino Solje: conceptualization, investigation, funding acquisition, methodology, validation, writing – review and editing, project administration, supervision, resources.
Acknowledgments
We thank Neurocenter Finland for coordinating this collaborative project and Research Nurse Tanja Kumpulainen for her invaluable help in this project. The study is also part of the research activities of the Finnish FinFTD Research Network.
Consent
Informed consent was not necessary.
Conflicts of Interest
E. Solje has served on the advisory board of Novartis, EISAI, and Roche Oy, served as a consultant for Novo Nordisk, and received honoraria for lectures from Lundbeck and Roche. J. Krüger has served on the advisory board of Novartis, Nutricia, EISAI, and Roche Oy, and received support for congress participation from Merck. J. Tiihonen has participated in a research project funded by Janssen-Cilag to his employing institution, has received lecture fees from Janssen-Cilag, Lundbeck, and Otsuka, and has served as a consultant to Healthcare Global Village, HLS Therapeutics, Janssen-Cilag, Orion, Teva, and WebMed Global.
Open Research
Data Availability Statement
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.